Lung cancer trials in France

In France 316 Also abroad 2746

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
Where
Boulogne-Billancourt, Paris
Age
18 years and over
People
100
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07739121
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Angers, Bobigny Cedex, Caen Cedex 5, Lyon, Montpellier Cedex 5, Nice Cedex 2, Paris, Pessac, Pierre-Bénite, Reims Cedex, Saint-Quentin, Strasbourg Cedex, Vannes
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00
Phase 2Taking people
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Where
Boulogne-Billancourt, Caen, Limoges, Lyon, Marseille, Paris, Pessac, Saint-Herblain, Strasbourg
Age
18 years and over
People
220 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05967689
No phaseTaking people
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
Where
Angers, Nantes, Rennes, Tours
Age
18 years and over
People
730
Run by
Nantes University Hospital
See details and how to joinNCT06481813
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Brest, Grenoble Cedex 9, Lille, Marseille, Montpellier, Paris, Saint-Herblain Cedex, Villejuif
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Where
Angers, Clermont-Ferrand, Dijon, Lille, Nice Cedex 2, Nimes Cedex 9, Paris Cedex 18, Reims, Saint-Quentin, Villefranche Sur Saone Cedex
Age
18 years and over
People
120 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Besancon Cedex, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain, Strasbourg Cedex 2, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
No phaseTaking people
Integrating Artificial Intelligence Into Lung Cancer Screening.
Where
Nice
Age
18 years to 80 years
People
2,722
Run by
Centre Hospitalier Universitaire de Nice
See details and how to joinNCT05704920
Phase 1/2Taking people
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Where
Grenoble Cedex 9, Lille, Lyon, Marseille, Paris, Paris Cedex 20, Pessac, Rennes, Saint-Herblain, Suresnes, Tours, Villejuif
Age
18 years and over
People
123 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06362252 · EU 2023-509629-36-00
Phase 1Taking people
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Where
Bordeaux, Lyon, Montpellier, Saint-Cloud, Saint-Herblain, Villejuif
Age
18 years and over
People
392 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00
Phase 2Taking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Angers, Avignon Cedex 9, Bordeaux, Dijon, Marseille, Paris, Saint-Herblain Cedex
Age
18 years and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Angers, Bordeaux, Caen Cedex 5, Lyon, Marseille, Montpellier, Paris, Pessac, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Avignon Cedex 9, Bordeaux, Boulogne-Billancourt, Caen Cedex 5, Chambéry, Dijon, Grenoble Cedex 9, Limoges, Paris, Pau, Saint-Herblain, Saint-Herblain Cedex, Saint-Malo Cedex, Toulouse Cedex 3, Tours
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 2Taking people
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
Where
Boulogne-Billancourt, Créteil, Nice Cedex 2, Toulon Cedex, Villejuif
Age
18 years and over
People
275
Run by
UNICANCER
See details and how to joinNCT07360743 · EU 2025-522655-26-00
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Lyon, Nantes, TOULOUSE, Villejuif
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Bordeaux, Caen, Lyon, Marseille, Montpellier, Nice, Paris, Villejuif
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Créteil, Grenoble Cedex 9, Marseille, Nice Cedex 2, Paris, Rennes, Saint-Herblain
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 1Taking people
A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Where
Bordeaux, Bron, Caen Cedex 5, Dijon, Lille, Paris, Saint-Herblain, Suresnes, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
180 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509572-42-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Not yet taking people in France
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Lyon, Marseille, Toulouse Cedex 9
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Lyon, Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 2Taking people
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Where
Angers, Bordeaux, Lyon, Marseille
Age
18 years and over
People
48 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT07203053 · EU 2025-522288-13-00
Phase 2Taking people
Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01
Where
Bordeaux, Brest, Caen Cedex 5, Créteil, Paris, Paris Cedex 20, Pierre-Bénite, Strasbourg Cedex, Villejuif
Age
18 years and over
People
100
Run by
Institut Gustave Roussy
See details and how to join2023-505924-71-00